Status:
NOT_YET_RECRUITING
Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence
Lead Sponsor:
Lei Li
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian cancer is the third most common malignant tumor in China's female reproductive system in terms of incidence rate and the first in terms of mortality. Surgery and systemic chemotherapy are the ...
Detailed Description
This research subjects are patients with epithelial ovarian cancer.The training set adopts case-control analysis, using the PASS software Test for Two Related Proportions in a Matched Case Control Des...
Eligibility Criteria
Inclusion
- Women over 18 years old
- Pathological diagnosis of stage I-IV epithelial ovarian cancer
- Eastern Cooperative Oncology Group (ECOG) score ≤ 2
- Expected survival period exceeding 6 months
- Within 8 weeks between diagnosis and enrollment
- Sign informed consent form
Exclusion
- Non epithelial ovarian tumors
- History of cancer in the past 5 years
- Received systematic treatment for ovarian cancer
- Gestation
- Previous bilateral oophorectomy
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
509 Patients enrolled
Trial Details
Trial ID
NCT06558019
Start Date
October 1 2024
End Date
December 31 2026
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China